Home » Stocks » NVTA

Invitae Corporation (NVTA)

Stock Price: $27.99 USD -0.09 (-0.32%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $28.23 +0.24 (0.86%) Jul 30, 7:47 PM
Market Cap 5.68B
Revenue (ttm) 318.97M
Net Income (ttm) -613.14M
Shares Out 194.00M
EPS (ttm) -3.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $27.99
Previous Close $28.08
Change ($) -0.09
Change (%) -0.32%
Day's Open 27.69
Day's Range 27.69 - 28.73
Day's Volume 1,894,283
52-Week Range 25.24 - 61.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 days ago - Zacks Investment Research

SEATTLE, July 22, 2021 /PRNewswire/ -- Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an...

1 week ago - PRNewsWire

SAN FRANCISCO, July 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2021 financial results on Tuesda...

1 week ago - PRNewsWire

With the global release of 5G connectivity, machine learning has become more of a secular trend than ever before.

Other stocks mentioned: AI, LTRN
1 week ago - The Dog of Wall Street

The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.

Other stocks mentioned: BNGO, OPK
2 weeks ago - The Motley Fool

Morgan Stanley warns investors 15% correction coming as market overvalued like dot-com days.

Other stocks mentioned: AMD, ARKG, NVDA, TSLA
2 weeks ago - Zacks Investment Research

Could Invitae become the first $1 trillion market cap healthcare company?

2 weeks ago - The Motley Fool

Cathie Wood's genomics ETF is making big bets on the "Genomic Age."

Other stocks mentioned: ARKG, EXAS, NTLA, PACB
2 weeks ago - The Motley Fool

Invitae (NVTA) closed the most recent trading day at $33.73, moving -1.03% from the previous trading session.

1 month ago - Zacks Investment Research

Invitae (NVTA) closed the most recent trading day at $34.25, moving +1.3% from the previous trading session.

1 month ago - Zacks Investment Research

In the latest trading session, Invitae (NVTA) closed at $32.79, marking a +1.52% move from the previous day.

1 month ago - Zacks Investment Research

SAN FRANCISCO, June 11, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021...

1 month ago - PRNewsWire

The genetic testing company's growth isn't the kind that impresses Wall Street.

1 month ago - The Motley Fool

These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies. The post 5 Healthcare Stocks to Buy for Their Game-Changing Potential ap...

Other stocks mentioned: BNGO, ILMN, MRNA, SDGR
1 month ago - InvestorPlace

Here are some of our experts' favorite gene editing plays for the long run.

Other stocks mentioned: CRSP, EDIT, NTLA
1 month ago - The Motley Fool

SAN FRANCISCO, June 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has begun offering early access to its new Personalized Cancer Monito...

1 month ago - PRNewsWire

Just like in poker, in some markets, the winner can take the whole pot. Can Invitae take home all the chips?

2 months ago - The Motley Fool

SAN FRANCISCO, May 25, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, is presenting multiple studies in multiple cancer types at the 2021 American Society of ...

2 months ago - PRNewsWire

San Francisco-headquartered Invitae Corp (NYSE: NVTA) defines itself as medical genetics company seeking to bring comprehensive genetic information into mainstream medicine, with the goal of improving o...

2 months ago - Benzinga

SAN FRANCISCO, May 20, 2021 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the William Blair 4...

2 months ago - PRNewsWire

It wasn't just the genetics company's soaring revenue growth.

2 months ago - The Motley Fool

Invitae (NVTA) closed at $29.95 in the latest trading session, marking a +1.66% move from the prior day.

2 months ago - Zacks Investment Research

Invitae CEO on the importance of genetic testing for preventative care

YouTube video

Invitae CEO Sean George joins "Power Lunch" to discuss genetic testing and what health care looks like after the pandemic.

2 months ago - CNBC Television

Invitae Corp (NYSE: NVTA) reported first-quarter FY21 results after the market closed Tuesday, wherein EPS loss of $0.63 came in worse than expectation of $0.59, sales of $103.6 million (+61% Y/Y) manag...

2 months ago - Benzinga

Sales were strong, but the medical genetics company still missed analysts' bottom-line expectations.

2 months ago - The Motley Fool

Invitae (NVTA) delivered earnings and revenue surprises of -5.00% and 1.58%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Invitae (NYSE:NVTA) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 21.25% over the past year to ($0.63), which missed the es...

2 months ago - Benzinga

SAN FRANCISCO, May 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 202...

2 months ago - PRNewsWire

More than 1,500 publicly traded companies are scheduled to report March quarter earnings this week, with heavy representation from energy exploration and production companies.

Other stocks mentioned: ATVI, DVN, LYFT, SKLZ
2 months ago - 24/7 Wall Street

Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.

3 months ago - Zacks Investment Research

Invitae (NVTA) closed at $36.66 in the latest trading session, marking a -1.5% move from the prior day.

3 months ago - Zacks Investment Research

Invitae Corporation (NVTA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

3 months ago - Zacks Investment Research

Invitae (NVTA) closed at $35.96 in the latest trading session, marking a -0.39% move from the prior day.

3 months ago - Zacks Investment Research

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced its plans to open a new laboratory and production facility in North Ca...

3 months ago - PRNewsWire

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2021 financial results on Tuesda...

3 months ago - PRNewsWire

WASHINGTON, April 19, 2021 /PRNewswire/ -- The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NY...

3 months ago - PRNewsWire

Can this leading clinical gene testing company add muscle to your portfolio?

3 months ago - The Motley Fool

SAN FRANCISCO, April 15, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced research showing one in six people with colorectal cancer harbor genet...

3 months ago - PRNewsWire

We're really excited that these genomics companies, says Ark's Simon Barnett

YouTube video

Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.

Other stocks mentioned: ADPT, ARKG, PACB
3 months ago - CNBC Television

All three companies have enjoyed major growth catalysts since the start of 2021.

Other stocks mentioned: AMRN, NNOX
3 months ago - The Motley Fool

SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Hum...

3 months ago - PRNewsWire

In an announcement on Monday, Invitae Corp (NYSE: NVTA) said it will receive £830 million investment from several investors, including the Japanese multinational conglomerate holding company, SoftBank G...

Other stocks mentioned: SFTBY
3 months ago - Invezz

Invitae Corp (NYSE: NVTA) has agreed to acquire Genosity Inc, a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests. De...

3 months ago - Benzinga

A group of investors including SoftBank Group Corp will invest $1.15 billion in Invitae Corp, the U.S. genetic diagnostics company said on Monday.

Other stocks mentioned: SFTBY
3 months ago - Reuters

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a...

3 months ago - PRNewsWire

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Management, a subsidiary of Softbank Gro...

3 months ago - PRNewsWire

Japanese technology firm SoftBank Group Corp (OTC: SFTBY) (OTC: SFTBF) is planning to infuse around $1.2 billion via convertible debt into genetic-testing provider Invitae Corp (NYSE: NVTA), the Wall St...

Other stocks mentioned: SFTBY
3 months ago - Benzinga

Eli Casdin on looking for opportunity in life sciences

YouTube video

Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.

Other stocks mentioned: FATE, XLV
3 months ago - CNBC Television

SAN FRANCISCO, April 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the availability of sponsored genetic testing for patients in the U.S.,...

3 months ago - PRNewsWire

AI applications will only increase as the world gets more efficient and these companies hope to take advantage.

Other stocks mentioned: GOOG, GOOGL, MDLA
3 months ago - The Motley Fool

About NVTA

Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. It has a collaboration with Pacific Biosciences of California, Inc. to develop a production-scale high... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 12, 2015
Stock Exchange
NYSE
Ticker Symbol
NVTA
Full Company Profile

Financial Performance

In 2020, NVTA's revenue was $279.60 million, an increase of 28.95% compared to the previous year's $216.82 million. Losses were -$602.17 million, 148.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for NVTA stock is "Buy." The 12-month stock price forecast is 42.00, which is an increase of 50.05% from the latest price.

Price Target
$42.00
(50.05% upside)
Analyst Consensus: Buy